HUTCHMED (China) Limited (AIM:HCM)
233.00
-2.00 (-0.85%)
Sep 10, 2025, 4:35 PM GMT+1
HUTCHMED (China) Employees
HUTCHMED (China) had 1,811 employees as of December 31, 2024. The number of employees decreased by 177 or -8.90% compared to the previous year.
Employees
1,811
Change (1Y)
-177
Growth (1Y)
-8.90%
Revenue / Employee
246.93K GBP
Profits / Employee
191.45K GBP
Market Cap
2.00B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 1,811 | -177 | -8.90% |
Dec 31, 2023 | 1,988 | -37 | -1.83% |
Dec 31, 2022 | 2,025 | 265 | 15.06% |
Dec 31, 2021 | 1,760 | 480 | 37.50% |
Dec 31, 2020 | 1,280 | 427 | 50.06% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
AstraZeneca | 94,300 |
GSK plc | 68,629 |
Haleon | 24,561 |
Smith & Nephew | 17,349 |
ConvaTec Group | 10,489 |
Hikma Pharmaceuticals | 9,500 |
Genus | 3,500 |
Oxford Nanopore Technologies | 1,382 |
HUTCHMED (China) News
- 6 days ago - HUTCHMED (China) Ltd (HCM) to Present New Data at Major Oncology Conferences | HCM stock news - GuruFocus
- 6 days ago - HUTCHMED Highlights Clinical Data to be Presented at the 2025 World Conference of Lung Cancer ... - GuruFocus
- 6 days ago - HUTCHMED Highlights Clinical Data to be Presented at the 2025 World Conference of Lung Cancer and the CSCO Annual Meeting 2025 - GlobeNewsWire
- 17 days ago - HUTCHMED CEO takes leave of absence; CFO Johnny Cheng appointed acting CEO - Seeking Alpha
- 17 days ago - HUTCHMED Announces CEO Leave of Absence and Interim Leadership Change | HCM stock news - GuruFocus
- 17 days ago - HUTCHMED Announces Appointment of Acting Chief Executive Officer - GlobeNewsWire
- 22 days ago - HUTCHMED Completes Patient Enrollment of SANOVO Phase III Trial of ... - GuruFocus
- 22 days ago - HUTCHMED Completes Patient Enrollment of SANOVO Phase III Trial of ORPATHYS® and TAGRISSO® Combination as a First-Line Therapy for Certain Lung Cancer Patients in China - GlobeNewsWire